Share
The AI for Oncology lab is a collaboration between the Netherlands Cancer Institute and the University of Amsterdam. Both institutes join forces in the development of AI algorithms to improve cancer treatment. The opening is on 24 June 2021.
Opening of AI for Oncology Lab on 24 June 2021
The AI for Oncology lab will officially and festively start and you are invited. Please register for the opening and after the registration you will receive a link. It is a digital meeting from 16h00 – 17h00.
Registration for the opening AI for Oncology 24 June 2021
The goal of the collaboration between the Netherlands Cancer Institute (NKI) and University of Amsterdam (UvA) is improved cancer treatment through the aid of Artificial Intelligence. A lot of complex information is acquired from patients during and prior to the treatment through medical imaging, pathology, DNA, and so on. AI solution can assist medical specialists finding and applying the right treatment based on all this in
email article
Patients with ultralow-risk breast cancer according to genomic assessment had excellent long-term outcomes regardless of clinical risk or whether they received adjuvant therapy, a new analysis of a randomized trial showed.
The 8-year breast cancer-specific survival (BCSS) was 99.2% among patients classified as clinically high-risk but ultralow-risk by the MammaPrint 70-gene assay. Patients with an ultralow-risk genomic assessment and low clinical risk had an 8-year BCSS of 99.7%. Freedom from distant metastasis at 8 years was 97.6% in patients who were clinically and genomically low-risk versus 95.0% for those who were clinically high-risk but genomically low-risk.
In patients with an ultralow-risk genomic assessment, the 8-year distant metastasis-free interval (DMFI) rate was 97.8% with no adjuvant systemic therapy. That compared with an 8-year DMFI of 97.4% in patients who received only adjuvant endocrine therapy and 94.9% in patients who received chemotherap
Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that data from the landmark MINDACT study will be shared at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting in an oral presentation.
Oral presentation at ASCO 2021 highlights long term data with higher than 99% 8-year breast cancer specific survival for patients with MammaPrint Ultra Low Risk status regardless of clinical risk